Christopher Goldring

Professor Christopher Goldring serves as Deputy Executive Dean of the Institute for Systems, Molecular and Integrative Biology at the University of Liverpool's Department of Pharmacology and Therapeutics. He co-directs the Human Liver Research Facility and the Joint Centre for Pharmacology and Therapeutics with XJTLU in Suzhou, China, while holding advisory roles with the MHRA Herbal Medicines Advisory Committee and MRC DiscoveryMedicineNorth doctoral training program.

Goldring's research centers on translational drug safety, focusing on developing humanised biologically-relevant models for predicting adverse drug reactions. Key initiatives include:

• Leading UKRI's 3Dbionet project to enhance 3D in vitro liver models
• Establishing pipelines for human primary liver cells (>380 samples since 2011)
• Developing industry-adopted roadmaps for pharmaceutical safety assessment
• Creating precision-cut tissue slice models for drug metabolism studies
• Investigating cholangiocarcinoma genomics and targeted therapies

Analysis of his 2020-2025 publications reveals three dominant trends: biomarker validation for drug-induced liver injury (DILI), physiological refinement of complex in vitro models (organoids, 3D cultures), and translational oncology focusing on biliary tract cancers. His work bridges academic research with pharmaceutical industry needs through twelve industry partnerships.

Recognition includes:

• Fellow of the British Pharmacological Society

Goldring supervises PhD research on stem cell-derived hepatocyte models, DILI biomarkers, and NRF2-mediated immune responses while securing major funding including:

• TransBioLine consortium (EU Commission, 2019-2025): $22M for translational biomarker development
• AMMF Charity projects (2017-2026): Cholangiocarcinoma immunosuppression studies
• NW Cancer Research (2023-2027): Uveal melanoma metastasis modeling
• MRC/BBSRC grants: Liver model reproducibility and physiological relevance

He co-directs the Centre for Drug Safety Science and Human Liver Research Facility, leading teams that include pharmaceutical partners (Janssen, Pfizer, Merck) and international academic collaborators to establish standards for preclinical safety assessment.